← FDA DRUG APPROVALS

FDA ANDA · ANDA205258

NEVIRAPINE

Sponsor: APOTEX

APPLICATION
ANDA205258
TYPE
ANDA
ORIGINAL APPROVAL
2014-04-03
LATEST ACTION
2014-04-03
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

NEVIRAPINEDiscontinued
NEVIRAPINE 400MG · TABLET, EXTENDED RELEASE · ORAL

Approval history

2014-04-03UNKNOWN · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →